A new, rapid method for measurng serum levels of nafcillin by spectrofluorometry is described. The method involves extraction of 2 ml of acidified serum with n-butyl chloride, subjecting the organic solvent layer to excitation at 340 rim, and measuring the relative intensity of emission fluorescence at 380 nm. An excellent linear correlation exists between serum levels of nafcillin and the relative intensity in a drug concentration range of 0.25 to 150 pg/ml. The results obtained by this spectrofluorometric technique are in complete accord with those obtained by the conventional microbiological assay using Staphylococcus aureus ATCC 6538P. The method is not interfered with by elevated levels of endogenous metabolic products or the presence of other drugs, including a number of antimicrobial agents. The assay is interfered with, however, by the presence of salicylates, for which appropriate correction can easily be made. A salicylate assay employing a spectrofluorometric technique is also described. Nafcillin (NF), a semisynthetic penicillinaseresistant penicillin, was first introduced for clinical use in 1963 (9). Since that time, NF has become a major antibiotic for the treatment of infections caused by penicilhinase-producing staphylococci. There is evidence that in clinical practice NF may be preferable to methicillin, another semisynthetic antistaphylococcal penicillin. The incidence of adverse drug reactions secondary to NF, including interstitial nephritis, appears to be lower than that due to methicillin (7), and the entry of NF into the cerebrospinal fluid has been shown to be more reliable and to produce higher cerebrospinal fluid levels than that of methicillin (4, 8) . In addition, NF has been shown to increase the susceptibility of Staphylococcus aureus to in vitro phagocytosis when the organism was treated with subinhibitory concentrations of the drug, whereas this phenomenon was not seen with methicillin or oxacillin under similar conditions (5). The major route of elimination of NF from the body is by hepatic metabolism, and close monitoring of drug levels in renal failure is not necessary (2). However, blood levels in severe hepatic failure may be unpredictably high. An accurate and rapid technique for measuring NF levels in body fluids would be desirable.
Nafcillin (NF), a semisynthetic penicillinaseresistant penicillin, was first introduced for clinical use in 1963 (9) . Since that time, NF has become a major antibiotic for the treatment of infections caused by penicilhinase-producing staphylococci. There is evidence that in clinical practice NF may be preferable to methicillin, another semisynthetic antistaphylococcal penicillin. The incidence of adverse drug reactions secondary to NF, including interstitial nephritis, appears to be lower than that due to methicillin (7) , and the entry of NF into the cerebrospinal fluid has been shown to be more reliable and to produce higher cerebrospinal fluid levels than that of methicillin (4, 8) . In addition, NF has been shown to increase the susceptibility of Staphylococcus aureus to in vitro phagocytosis when the organism was treated with subinhibitory concentrations of the drug, whereas this phenomenon was not seen with methicillin or oxacillin under similar conditions (5) . The major route of elimination of NF from the body is by hepatic metabolism, and close monitoring of drug levels in renal failure is not necessary (2) . However, blood levels in severe hepatic failure may be unpredictably high. An accurate and rapid technique for measuring NF levels in body fluids would be desirable.
To date, serum levels of NF have been determined by a conventional microbiological assay method using standard strains of a susceptible bacterium (6) . This method usually requires approximately 24 h for completion. In addition, microbiological assays are often interfered with by the presence in the serum of antimicrobial agents other than the test antibiotic, so that specific inactivation or elimination of the undesired drug must be utilized. NF contains an aromatic moiety, naphthalene, which can be used as a source of fluorescence emission when excited at appropriate wavelengths (12) . Using this property, a rapid spectrofluorometric assay method for the determination of serum NF levels has been developed. A comparison of this method with the currently employed microbiological method and an evaluation of the specificity of the newly developed method are reported in this study.
MATERIALS AND METHODS
Chemicals. Sodium nafcillin (lot W762417) was supplied by Wyeth Laboratories, Philadelphia. Acetylsalicylic acid (ASA), bilirubin (lot 127C-0446), creatinine phosphate (lot 55C-0163), and human hemoglobin type IV (lot 118C-4045) were Analytical procedures. (i) Spectrofluorometric assay of NF. To 2-ml serum samples in 15-ml graduated, ground-glass-stoppered centrifuge tubes was added 2.5 ml of 2 M phosphoric acid-NaOH buffer (pH 1.95). The solutions were mixed on a Vortex mixer for a few seconds. After 5 min at room temperature, 4.5 ml of n-butyl chloride was added to the tubes, and the tubes were gently mixed with a to-and-fro motion of approximately 100 motions per min on a mechanical shaker (Dubnoff Metabolic Shaking Incubator, model P/S, Precision Scientific Co., Chicago, Ill.) for 5 min. The samples were then centrifuged for 10 min (2,000 x g) at room temperature in an International Centrifuge, model PR-6. Samples of 4 ml of the organic solvent layer (upper) were transferred to clean, ground-glass-stoppered, 15-ml, graduated centrifuge tubes and were used to determine the relative intensity of fluorescence. The samples were excited at a 340-nm wavelength, and the relative intensities at 380 nm were measured using a Perkin-Elmer MPF-3 Spectrofluorometer (Perkin-Elmer, Norwalk, Conn.). The slit widths for both the excitation and the emission were set at 10 nm, with the sensitivity of the recorder set at The relative intensity obtained from the n-butyl chloride layer of a serum specimen without NF was used to correct for background fluorescence (4.0 ± 0.13 relative intensity units).
factor of 10. A linear relationship existed between NF levels and relative intensity (r > 0.99) in the concentration range of 0.25 to 150 ,tg of NF per ml. The coefficient of variation at the serum NF concentration range from 5 to 50 ug/ml was 3.65%.
To test the feasibility of using the spectrofluorometric assay to determine serum NF levels in smaller clinical specimens such as would be necessary in pediatric patients or cerebrospinal fluid, standard curves were constructed using 1-mi samples of pooled normal human serum containing 0, 1.0, 2.5, 5.0, 10.0, 25.0, and 50.0 ug of NF per ml. A linear relationship existed between NF levels and relative intensity (r > 0.99) for the 1-ml samples in the concentration range described.
(ii) Determination of serum NF levels in the presence of aspirin. Aspirin (ASA) as well as its active metabolite, salicylate (SL) ion, interfered with the quantitation of serum NF levels. The fluorescent nature of SL is well established (3) . Under the present assay conditions, both ASA and SL when excited at 340 nm gave maximum fluorescence emission at 450 nm. The emission peak was broad and exhibited some intensity over background at 380 nm (Fig. 2) . To determine the degree of interference at 380 nm due to the presence of SL, as well as to establish a correction factor for the presence of SL, pooled normal human serum was adjusted to contain either 0, 50.0, 100.0, peak at 380 nm and the peak at 450 nm. SL levels were also determined by the colorimetric method ofTrinder (11) .
To test the ability of this spectrofluorometric method to accurately determine the SL levels in a patient's serum, the serum SL levels in six patients on ASA therapy were determined by both the spectrofluorometric and colorimetric methods (3, 11) .
(iii) Microbiological assay of NF. To serve as a standard curve, pooled normal human serum samples were prepared in the following concentrations: 0, 0.5, 1.0, 2.5, 5.0, 12.5, 25.0, 50.0, 100.0, and 150.0 jug of NF per ml. Aliquots of these samples were frozen at -20°C until analysis. Serum samples of 10 patients on NF therapy were obtained and frozen at -20°C until analysis. The microbiological assay was performed with tryptic soy agar (Difco Laboratories, Detroit, Mich.) and S. aureus (ATCC 6538P) according to a modified disk diffusion method as previously described (1) . The results obtained by the microbiological asay were compared with those obtained by spectrofluorometry.
RESULTS
Determination of NF levels in human serum specimens. Ten blood specimens were obtained from patients on NF therapy, and the levels of NF were determined by both the new spectrofluorometric method and the conventional microbiological assay as described above. Serum specimens were used, and the results are shown in Table 1 . Excellent correlation was demonstrated between the two assay techniques (r = 0.997).
Effect of endogenous metabolic products on the assay procedure. To determine whether the assay procedure would be interfered with by elevated levels of endogenous metabolic products, various compounds were added to the serum specimens. The compounds tested (with the highest concentrations examined shown in parentheses) were as follows: bilirubin (500 ug/ ml), urea (400 ,ug/ml), creatinine phosphate (150 Method of agar diffusion microbiological assay (1) .
,ug/ml), and hemoglobin (150 ug/ml). NF levels studied in the presence of these compounds ranged from 0 to 50 ug/ml. There is no evidence that these metabolic products interfered with the assay procedure. Effect of common therapeutic agents on the assay procedure. To determine potential interference with the spectrofluorometric assay for NF due to the presence of other therapeutic agents, many commonly used drugs were added to the system. The drugs and concentrations tested included carbenicillin (200 ug/ml), chloramphenicol (30 ,ug/ml), erythromycin (20 yig/ ml), gentamicin (20 itg/ml), sulfamethoxazole (200 ,ug/ml), sulfisoxazole (200 1g/ml), trmethoprim (20 ig/ml), acetaminophen (50 ug/ml), ASA (500 ug/ml), diazepam (1 ug/ml), digitoxin (25 ng/ml), phenobarbital (50 ,ug/ml), phenytoin (20 ,ug/ml), and sodium salicylate (200 ,ug/ml). NF levels tested again ranged from 0 to 50 ,tg/ ml. There was no evidence of any significant interference by the presence of drugs tested except for SL (ASA and sodium salicylate).
Effect of SL on the assay prmcedure. When it was shown that SL interfered with the assay method, the problem was further pursued to determine whether the method could be used to assay for levels of SL as well as for NF. When excited at 340 nm, the mimum intensity of fluorescence of SL in n-butyl chloride occurred at 450 nm. The emission peak was broad and exhibited some intensity over background at 380 nm (Fig. 2) . When SL was present in serum at 0, 50.0, 100.0, 200.0, or 400.0 ,ug/ml, the ratio between the intensity of fluorescence at 380 nm and 450 nm was calculated for each SL level. The average value of these ratios was shown to be constant at 0.63. From this ratio, the following equation was constructed to determine NF levels when SL was present: Relative intensity (RI)N = RIW+sL) _ (RI& x 0.63). To determine the validity of this equation, pooled normal human serum was adjusted to contain either known amounts of SL, NF, or SL and NF as described in Materials and Methods. The above equation was used to calculate NF levels in samples in which both NF and SL were present. Table 2 shows the results of this study. There was an excellent agreement between the measured and known amounts of NF in samples in which both were present.
To determine the ability of the spectrofluorometric assay to accurately determine the serum SL levels, serum samples from six patients on ASA therapy were analyzed by the spectrofluorometric and colorimetric techniques (11) ( 
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The quantitation of NF by the spectrofluorometric assay is not interfered with by elevated levels of bilirubin, blood urea nitrogen, creatinine, or hemoglobin and therefore would be useful in patients whose serum contains abnormal levels of endogenous metabolites. The only therapeutic agents tested which interfere with the quantitation of serum NF levels are ASA and its active metabolite, SL. The presence of SL in serum can be readily detected by the appearance of an emission peak at 450 nm. A correction factor can then be employed to accurately quantitate the serum NF level in the presence of SL. SL levels can be simultaneously determined. This spectrofluorometric assay offers a new, rapid, sensitive, and reliable technique for the quantitation of serum NF levels.
